Saturn is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. The first patient will be enrolled
According to VGX Pharmaceuticals, VGX-1027 is the first of a new class of immune modulators that inhibits the production of several proinflammatory cytokines, which are responsible for the
The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. The company said that, additionally, a range of active compounds are protected,
Cetirizine hydrochloride chewable, which will be marketed as two separate over-the-counter (OTC) products in two strengths, 5 mg and 10 mg, is an antihistamine drug, which is used
Forticell’s wholly owned subsidiary Hapto Biotech will provide Fibrin MicroBeads along with proprietary research protocols and methods developed at its Hapto Biotech research laboratories in Israel for the
Vidaza has been designated as an orphan medicinal product in the European Union (EU) for the treatment of myelodysplastic syndrome (MDS), which, if approved, entitles the drug to
AvalonRx, Avalon’s proprietary drug discovery platform, was used to screen, identify and characterize compounds from Novartis’s proprietary compound library. Avalon said that candidate hit compounds were successfully identified
The company said that the revised labeling recognizes the capability of King’s enhanced processes to reduce Factor V light chain content to undetectable levels using currently available methodologies.
The study will enroll 300 patients with mild to moderate psoriasis at 20 investigational centers across the US. The placebo- and active-controlled study will evaluate three concentrations of
The company said that the goal of this Phase IIa study will be to optimize dosing in order to fully exploit the therapeutic potential of PRX302, while maintaining
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.